Creative Drug Pricing Hindered By Medicaid Best Price, Stakeholders Say
This article was originally published in The Pink Sheet Daily
Executive Summary
Requirement that drug manufacturers pay Medicaid rebates based on the best price available to any purchaser impedes payer efforts to negotiate value-based pricing for costly drugs, Pfizer and Express Scripts say.
You may also be interested in...
CMS Wants To Facilitate Value-Based Discounts For HCV Drugs In Medicaid
CMS requests information from hepatitis C manufacturers on how value-based purchasing arrangements might work in Medicaid. Agency also urges state Medicaid directors to relax overly strict coverage requirements for the drugs.
HHS Raises Profile In Drug Costs Discussion
On Nov. 20, HHS will host a day-long forum on pharmaceuticals, including a look at high-cost specialty drugs and innovative purchasing strategies.
Melanoma Approvals Break New Ground In Immunotherapy
First adjuvant and combination approvals for immuno-oncology could help revive Yervoy in melanoma; Amgen’s oncolytic cancer vaccine emerges as new mechanism for select patients, with room to grow.